CN102712921B - 特异用于胞外基质蛋白的氨基酸序列rgd的人源化抗体及其用途 - Google Patents

特异用于胞外基质蛋白的氨基酸序列rgd的人源化抗体及其用途 Download PDF

Info

Publication number
CN102712921B
CN102712921B CN201080042356.1A CN201080042356A CN102712921B CN 102712921 B CN102712921 B CN 102712921B CN 201080042356 A CN201080042356 A CN 201080042356A CN 102712921 B CN102712921 B CN 102712921B
Authority
CN
China
Prior art keywords
seq
sequence
hu33e10
rgd
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080042356.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN102712921A (zh
Inventor
尚卡·库马
曹仲欣
鹤下直也
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kidswell Bio Corp
Original Assignee
Gene Techno Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gene Techno Science Co Ltd filed Critical Gene Techno Science Co Ltd
Publication of CN102712921A publication Critical patent/CN102712921A/zh
Application granted granted Critical
Publication of CN102712921B publication Critical patent/CN102712921B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201080042356.1A 2009-09-24 2010-09-22 特异用于胞外基质蛋白的氨基酸序列rgd的人源化抗体及其用途 Expired - Fee Related CN102712921B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27243809P 2009-09-24 2009-09-24
US61/272,438 2009-09-24
PCT/JP2010/067017 WO2011037271A1 (en) 2009-09-24 2010-09-22 Humanized antibodies specific for amino acid sequence rgd of an extracellular matrix protein and the uses thereof

Publications (2)

Publication Number Publication Date
CN102712921A CN102712921A (zh) 2012-10-03
CN102712921B true CN102712921B (zh) 2017-03-01

Family

ID=43796008

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080042356.1A Expired - Fee Related CN102712921B (zh) 2009-09-24 2010-09-22 特异用于胞外基质蛋白的氨基酸序列rgd的人源化抗体及其用途

Country Status (9)

Country Link
US (1) US8617829B2 (cg-RX-API-DMAC7.html)
EP (1) EP2480665A4 (cg-RX-API-DMAC7.html)
JP (1) JP5781504B2 (cg-RX-API-DMAC7.html)
KR (1) KR101809761B1 (cg-RX-API-DMAC7.html)
CN (1) CN102712921B (cg-RX-API-DMAC7.html)
AU (1) AU2010299017B2 (cg-RX-API-DMAC7.html)
CA (1) CA2772230C (cg-RX-API-DMAC7.html)
IN (1) IN2012DN01981A (cg-RX-API-DMAC7.html)
WO (1) WO2011037271A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2703785T3 (es) * 2013-04-08 2019-03-12 Regentys Corp Método y composición para tratar una enfermedad inflamatoria intestinal sin colectomía
EP3286218B1 (en) * 2015-04-20 2022-11-30 Consejo Superior de Investigaciones Cientificas Agents binding specifically to human cadherin-17, human cadherin-5, human cadherin-6 and human cadherin-20 rgd motif
EP3543337B1 (en) * 2016-11-18 2022-04-20 Astellas Pharma Inc. Novel anti-human muc1 antibody fab fragment
TWI795415B (zh) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
EP3795590A4 (en) 2018-05-17 2022-05-04 Astellas Pharma Inc. COMPLEX WITH ANTI-HUMAN MUC1 ANTIBODY FAB FRAGMENT, PEPTIDE LINKER AND/OR LIGAND
US12065503B2 (en) 2018-10-10 2024-08-20 Astellas Pharma Inc. Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1688604A (zh) * 2001-09-25 2005-10-26 株式会社免疫生物研究所 重组抗骨桥蛋白抗体及其用途
WO2008050907A1 (fr) * 2006-10-26 2008-05-02 Gene Techno Science Co., Ltd. Anticorps dirigé contre rgd dans une séquence d'acides aminés d'une protéine de matrice extracellulaire et procédé de fabrication et utilisation de celui-ci

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB9519667D0 (en) 1995-09-27 1995-11-29 Univ Manchester Pharmaceutical composition
JP2003517284A (ja) 1999-04-15 2003-05-27 チルドレンズ メディカル センター コーポレーション 免疫応答を変調する方法及び組成物
JP2003528322A (ja) 2000-03-23 2003-09-24 グラクソ グループ リミテッド オステオポンチンのインヒビターのスクリーニング方法
JP2007106767A (ja) * 2001-04-05 2007-04-26 Meneki Seibutsu Kenkyusho:Kk 抗オステオポンチン抗体およびその用途
MXPA03009052A (es) 2001-04-05 2004-10-15 Immuno Biological Lab Co Ltd Anticuerpo anti-osteopontina y uso del mismo.
US20070274993A1 (en) 2003-05-23 2007-11-29 Immuno-Biological Laboratories Co., Ltd. Immunocompetent Cell Activation Inhibitor and Use Thereof
JP5736176B2 (ja) * 2008-04-24 2015-06-17 株式会社ジーンテクノサイエンス 細胞外マトリックスタンパク質のアミノ酸配列ｒｇｄに特異的なヒト化抗体およびその使用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1688604A (zh) * 2001-09-25 2005-10-26 株式会社免疫生物研究所 重组抗骨桥蛋白抗体及其用途
WO2008050907A1 (fr) * 2006-10-26 2008-05-02 Gene Techno Science Co., Ltd. Anticorps dirigé contre rgd dans une séquence d'acides aminés d'une protéine de matrice extracellulaire et procédé de fabrication et utilisation de celui-ci

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RGD在整合素中的作用及纤粘蛋白介导的生物学过程;冯必钧等;《世界科技研究与发展》;20081231;第30卷(第6期);713-717 *

Also Published As

Publication number Publication date
WO2011037271A1 (en) 2011-03-31
CA2772230A1 (en) 2011-03-31
US8617829B2 (en) 2013-12-31
KR20120078725A (ko) 2012-07-10
EP2480665A4 (en) 2013-04-03
CA2772230C (en) 2019-01-08
AU2010299017B2 (en) 2014-02-06
IN2012DN01981A (cg-RX-API-DMAC7.html) 2015-07-24
EP2480665A1 (en) 2012-08-01
AU2010299017A1 (en) 2012-03-15
JP2013505702A (ja) 2013-02-21
JP5781504B2 (ja) 2015-09-24
CN102712921A (zh) 2012-10-03
KR101809761B1 (ko) 2017-12-15
US20120219503A1 (en) 2012-08-30

Similar Documents

Publication Publication Date Title
CN101918555B (zh) 人源化抗整联蛋白α9抗体及其应用
CN102712921B (zh) 特异用于胞外基质蛋白的氨基酸序列rgd的人源化抗体及其用途
CN104530233B (zh) 细胞外基质蛋白的氨基酸序列rgd的特异性人源化抗体及其应用
US8735552B2 (en) Generation, expression and characterization of the humanized K33N monoclonal antibody

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170301

Termination date: 20200922

CF01 Termination of patent right due to non-payment of annual fee